Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of colestilan in paediatric CKD patients with hyperphosphataemia not on dialysis
2012-002582-35Phase 3Terminated
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of colestilan in hyperphosphatemia and chronic kidney disease (CKD), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Primary. Started Oct 2012; status: terminated.
02
Drugs
colestilan
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2012-002582-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002582-35.